Clovis Oncology


Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.32 (0.55%)
Intraday High$59.24
Intraday Low$56.76
Data as of 04/28/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
04/27/17Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment
SALT LAKE CITY, Utah & BOULDER, Colo., April 27, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis' PARP inhibitor, Rubraca.  Financial terms of the deal were not disclosed.Under the agreement, Myriad will submit a supplementary premarket approval (sPMA) application under its existing PMA for BRACAnalysis CDx to include Rubraca.  The... 
Printer Friendly VersionDownload PDF
04/20/17Clovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on May 3
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 20, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis O... 
Printer Friendly VersionDownload PDF
03/28/17Clovis Oncology Announces Data Presentations at AACR Annual Meeting 2017
Abstracts provide new insights into rucaparib’s mechanism of action and function in multiple disease and therapy settings FDA approved Rubraca® (rucaparib) tablets in late 2016 as monotherapy treatment for women with BRCA-mutated advanced ovarian cancer BOULDER, Colo.--(BUSINESS WIRE)--Mar. 28, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that rucaparib preclinical data will be presented at the Am... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
2:30 p.m. MT
Q1 2017 Clovis Oncology, Inc. Earnings Conference Call
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.